SOURCE: Tulip BioMed, Inc.

September 18, 2007 08:28 ET

Tulip BioMed, Inc. Announces Retention of Two Key Regional Independent Distributors for Its Disposable Line of Products

SAN DIEGO, CA--(Marketwire - September 18, 2007) - Tulip BioMed™, Inc. (PINKSHEETS: TPBD), a developer of medical devices and patented technologies for the living tissues market, including plastic, cosmetic, and orthopedic surgeries (the "Company"), today announced the retention of Ms. Marjan Mamooie and Mr. Frank J. Perroni as independent distributors for its Tulip BioMed disposable products. Ms. Mamooie will be primarily responsible for sales in Southern California (ranging from Santa Barbara to San Diego) and Mr. Perroni will be primarily responsible for sales in the five boroughs of New York City (with intermittent reach into the Tri-State region).

Ms. Mamooie, who resides in Southern California, has spent four years as a pharmaceutical and medical device sales representative and has been an independent distributor for a variety of products sold in the plastic and cosmetic surgery arenas. Mr. Perroni, who resides in New York City, has an extensive medical sales and sales management history, including emergency medical disposable products for a major pharmaceutical company.

The region of the country that includes Southern California, as cited by the American Society of Plastic Surgeons, has approximately 3.0 million cosmetic procedures performed annually. A great percentage of those procedures are performed in Southern California, and those procedures are expected to grow at a rate of about 10% per year. The region of the country that includes the Tri-State Area, as cited by the American Society of Plastic Surgeons, has approximately 2.3 million cosmetic procedures performed annually. A great percentage of those procedures are performed in The Tri-State Area, and those procedures are also expected to grow at a rate of about 10% per year. Total cosmetic procedures for 2006 in the United States was approximately 11.0 million and continues to grow annually, as the aging baby boomer tide helps shape the future of the cosmetic and plastic surgery industries.

Dori K. Gavitt, director, marketing and sales, noted that, "We believe that retaining independent distributors, who are already making visits and calls to physicians who are potential customers, is an effective and efficient way to maximize our resources. In-house sales representatives increase overhead and administrative expenses, and our collective goal is to keep these costs at a minimum. By participating in new sales revenue, independent distributors have a natural motivation to enhance the presence of products in the community so as to maximize their return on investment. We are very pleased that Marjan and Frank have joined our team and we look forward to their assistance in helping Tulip BioMed generate new sales opportunities, augment growth, and assist in our primary corporate objective -- enhancing shareholder value."

About Tulip BioMed, Inc.

Tulip BioMed, Inc., a Nevada corporation, has its operations based in San Diego, California. Founded in 2004, Tulip BioMed, Inc. is a medical devices company that manufactures and distributes technologies for the living tissue markets, including plastic and cosmetic surgery, biopsy, and orthopedic surgery. Tulip BioMed, Inc. manufactures, markets, and distributes medical devices, to physicians, clinics, military, health organizations, hospitals and other distribution outlets. For more information, please call us at 1-800-97TULIP (1-800-978-8547), or visit our website at: www.tulipbiomed.com. Products are available for sale at www.tulipdisposable.com.

Safe Harbor: This press release contains certain forward-looking information about Tulip BioMed, Inc., which is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Tulip BioMed, Inc., that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: our lack of operating revenue and earnings history, our need for additional capital to pursue our business strategy. We are a non-reporting company and as such do not make periodic filings with the Securities and Exchange Commission. We trade on the Pink Sheets and there can be no assurances that a liquid market will develop in our securities. Readers are cautioned not to place undue reliance on these forward-looking statements. Tulip BioMed, Inc. does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact Information

  • CONTACT:

    Premier Funding Service
    Kelly Black
    President

    Heather Kerwin
    Investor Relations

    (480) 649-8224 Office
    (480) 898-0406 Fax